Voices of Change: Flyrcado in Action

Join us for a dynamic breakfast panel where early adopters share how Flyrcado™ (flurpiridaz F 18) injection can reshape cardiac imaging and care. Hear real-world stories from both imagers and referring cardiologists about the impact of Cardiac PET on clinical practice and patient outcomes. Gain practical insights, ask questions, and connect with peers driving innovation in coronary artery disease (CAD) diagnosis and management.

RSVP Today!

*In compliance with the PhRMA Code of Ethics, there is no alcohol permitted at this event.

This event is not part of ACC.26, as planned by its Program Committee, and does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Important Safety Information

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. 

Contraindications

None

Warnings and Precautions

Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. 

Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and healthcare providers. Advise patients to hydrate before and after administration and to void.

Adverse Reactions

Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. 

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch 

For full Prescribing Information, click here. 

GE HealthCare | Privacy Policy | Terms of Use | Contact Us | Unsubscribe

500 W. Monroe Street | Chicago, IL 60661

© 2026 GE HealthCare
GE is a trademark of General Electric Company used under trademark license.
March 2026 | JB13397US